National and Kapodistrian University of Athens
Η συμβολή του Infliximab (anti-TNFa) ως αντιουλωτικού παράγοντα στην επέμβαση του γλαυκώματος
Abstract
dc:descriptionGlaucoma filtration surgery induces tissue injury that stimulates the body to commence a complex series of precisely controlled events, which define the process of wound healing. TNF-a plays a vital role throughout this process, as it participates in clotting, inflammation and apoptosis. Infliximab is a chimeric monoclonal antibody that binds to both soluble and transmembrane proinflammatory cytokine TNF-α. We hypothesized that blocking TNF-a with Infliximab would reduce both inflammation and fibrosis post glaucoma filtration surgery and consequently enhance bleb survival. Our results have shown that trabeculectomies in the Infliximab group failed faster and displayed more scarring, compared to the control and MMC group. Vascularity though was less significant in the Infliximab group compared to the control group. This outcome, suggests that the Infliximab doses used in this pilot study, resulted in a subconjunctival TNF-a concentration, which probably acted as a stimulator to fibroblasts, but not for angiogenesis. In order to reproduce the current golden standard technique of MMC application, Infliximab was administered under the conjunctiva through soaked sponges, in a pre-determined filtration area and then irrigated with saline. It is unknown whether the same concentrations of Infliximab would have produced different clinical outcomes, had it not been washed out or had it been administered through a subconjunctival injection at the beginning of surgery. Our data also showed a statistically significant decrease in cellular density in the MMC group, compared to the other groups. This echoes multiple studies demonstrating that MMC causes wide spread cell death and apoptosis. No differences were found in cellular density and scarring amongst various concentrations of Infliximab. This could imply that for topical Infliximab administration, larger concentration variances would be required to produce a detectable clinical difference. In conclusion, our outcomes indicate that Infliximab, when administered subconjunctivally during experimental glaucoma filtration surgery, in concentrations ranging from 10-50 mg/ml, accelerates scarring and bleb failure. The ideal anti-fibrotic agent, which will modulate wound healing, whilst minimizing side effects is yet to be defined.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nikita, Eleni
- Νικήτα, Ελένη
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44282